SCHEMBL6344277

SCHEMBL6344277

COc1cc(C[C@H](N)CO)ccc1O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.71
MMP1 P03956 1/20 0.71
FOS P01100 1/20 0.66
TTR P02766 1/20 0.66
JUN P05412 1/20 0.66
NR3C1 P04150 1/20 0.66
HSD17B1 P14061 1/20 0.66
HSD17B2 P37059 1/20 0.66
ALOX15 P16050 2/20 0.60
ALOX12 P18054 2/20 0.60
TSHR P16473 3/20 0.58
TAAR1 Q96RJ0 2/20 0.58
MAPK1 P28482 1/20 0.58
LMNA P02545 1/20 0.57
GLA P06280 1/20 0.57
ALDH1A1 P00352 2/20 0.51
GAA P10253 2/20 0.51
NFKB1 P19838 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
PTPN1 P18031 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11695436 0.87 ALOX15 (0.66) CYP3A4MMP1FOSTTRJUN
SCHEMBL7298435 0.87 LDHA (0.58) CYP3A4MMP1FOSTTRJUN
SCHEMBL10776070 0.87 LDHA (0.58) CYP3A4MMP1FOSTTRJUN
SCHEMBL7290411 0.87 LDHA (0.58) CYP3A4MMP1FOSTTRJUN
Hydrochloric Acid SCHEMBL11696571 0.86 ALOX15 (0.64) CYP3A4MMP1FOSTTRJUN
3-O-Methyl-Alpha-Methyldopamine SCHEMBL9434236 0.83 FOS (0.75) CYP3A4MMP1FOSTTRJUN
(+)-Secoisolariciresinol SCHEMBL31677395 0.83 CYP3A4 (1.00) CYP3A4MMP1FOSTTRJUN
(+)-Secoisolariciresinol SCHEMBL21028109 0.83 CYP3A4 (1.00) CYP3A4MMP1FOSTTRJUN
(+)-Secoisolariciresinol SCHEMBL30334899 0.83 CYP3A4 (1.00) CYP3A4MMP1FOSTTRJUN
(+)-Secoisolariciresinol SCHEMBL325398 0.83 CYP3A4 (1.00) CYP3A4MMP1FOSTTRJUN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906100-B2 Compounds and compositions derived from olives and methods of the use thereof LAVIPHARM S.A. (GR) 2005-06-14 US disclosed
EP-1474130-A2 USE OF COMPOUNDS AND COMPOSITIONS DERIVED FROM OLIVES FOR PROTECTING CELLS AGAINST DNA DAMAGE LAVIPHARM S.A. (GR) 2004-11-10 EP disclosed
US-20030185921-A1 COMPOUNDS AND COMPOSITIONS DERIVED FROM OLIVES AND METHODS OF USE THEREOF THALLIUM HOLDING COMPANY, LLC 2003-10-02 US disclosed
WO-2003066034-A2 USE OF COMPOUNDS AND COMPOSITIONS DERIVED FORM OLIVES FOR PROTECTING CELLS AGAINST DNA DAMAGE LAVIPHARM S.A. (GR) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030185921-A1 COMPOUNDS AND COMPOSITIONS DERIVED FROM OLIVES AND METHODS OF USE THEREOF OGG1, SOD3, LIG3 CYP3A4 4148/4885MMP1 401/4885FOS 1042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.